X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs TTK HEALTHCARE - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB TTK HEALTHCARE DR. REDDYS LAB/
TTK HEALTHCARE
 
P/E (TTM) x 31.9 22.6 141.3% View Chart
P/BV x 3.4 7.6 45.0% View Chart
Dividend Yield % 0.8 0.4 201.4%  

Financials

 DR. REDDYS LAB   TTK HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
TTK HEALTHCARE
Mar-14
DR. REDDYS LAB/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,788663 420.3%   
Low Rs1,902399 476.6%   
Sales per share (Unadj.) Rs860.8535.6 160.7%  
Earnings per share (Unadj.) Rs57.115.9 357.9%  
Cash flow per share (Unadj.) Rs122.020.0 609.2%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Dividend yield (eoy) %0.90.8 113.3%  
Book value per share (Unadj.) Rs757.7137.6 550.6%  
Shares outstanding (eoy) m165.917.77 2,135.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.0 274.7%   
Avg P/E ratio x41.133.3 123.3%  
P/CF ratio (eoy) x19.226.5 72.5%  
Price / Book Value ratio x3.13.9 80.2%  
Dividend payout %35.025.1 139.7%   
Avg Mkt Cap Rs m389,0344,127 9,425.6%   
No. of employees `00023.51.7 1,377.3%   
Total wages/salary Rs m32,149607 5,299.9%   
Avg. sales/employee Rs Th6,070.82,436.7 249.1%   
Avg. wages/employee Rs Th1,366.6355.2 384.8%   
Avg. net profit/employee Rs Th402.572.5 554.8%   
INCOME DATA
Net Sales Rs m142,8104,162 3,431.4%  
Other income Rs m1,55261 2,535.9%   
Total revenues Rs m144,3624,223 3,418.5%   
Gross profit Rs m23,512197 11,929.0%  
Depreciation Rs m10,77232 33,981.1%   
Interest Rs m78830 2,635.5%   
Profit before tax Rs m13,504197 6,865.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,38073 6,016.5%   
Profit after tax Rs m9,468124 7,641.6%  
Gross profit margin %16.54.7 347.6%  
Effective tax rate %32.437.0 87.6%   
Net profit margin %6.63.0 222.7%  
BALANCE SHEET DATA
Current assets Rs m104,9841,629 6,445.9%   
Current liabilities Rs m68,9381,058 6,517.1%   
Net working cap to sales %25.213.7 184.0%  
Current ratio x1.51.5 98.9%  
Inventory Days Days7430 249.7%  
Debtors Days Days10434 308.4%  
Net fixed assets Rs m104,385556 18,764.2%   
Share capital Rs m83078 1,068.2%   
"Free" reserves Rs m124,886878 14,219.1%   
Net worth Rs m125,7161,069 11,756.9%   
Long term debt Rs m25,089159 15,809.1%   
Total assets Rs m225,4432,399 9,395.8%  
Interest coverage x18.17.6 239.3%   
Debt to equity ratio x0.20.1 134.5%  
Sales to assets ratio x0.61.7 36.5%   
Return on assets %4.56.4 71.0%  
Return on equity %7.511.6 65.0%  
Return on capital %9.718.5 52.6%  
Exports to sales %00.8 0.0%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs mNA33 0.0%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m72,62333 220,738.6%   
Fx outflow Rs m18,91663 29,935.1%   
Net fx Rs m53,707-30 -177,309.3%   
CASH FLOW
From Operations Rs m18,030127 14,241.7%  
From Investments Rs m-14,883-146 10,193.8%  
From Financial Activity Rs m-4,44022 -20,274.0%  
Net Cashflow Rs m-1,2363 -49,440.0%  

Share Holding

Indian Promoters % 25.5 65.4 39.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 5.2 678.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 25.8 59.3%  
Shareholders   75,885 12,723 596.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Remains Rangebound; HDFC AMC & Reliance Nippon Tumble Over 8%(12:30 pm)

Stock markets in India are trading in a range with positive bias in the afternoon session amid firm cues in the Asian markets and a recovery in rupee. Gains are largely seen in metal stocks and energy stocks.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 19, 2018 12:47 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AUROBINDO PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS